Cargando…
Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) represent a technical revolution in integrative neuroscience. However, the first used ligands exhibited dose-dependent selectivity for their molecular target, leading to potential unspecific effects. Compound 21 (C21) was recently...
Autores principales: | Goutaudier, Raphaël, Coizet, Véronique, Carcenac, Carole, Carnicella, Sebastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500623/ https://www.ncbi.nlm.nih.gov/pubmed/32946510 http://dx.doi.org/10.1371/journal.pone.0238156 |
Ejemplares similares
-
DREADDs: The Power of the Lock, the Weakness of the Key. Favoring the Pursuit of Specific Conditions Rather than Specific Ligands
por: Goutaudier, Raphaël, et al.
Publicado: (2019) -
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based
DREADDs in Vitro and in Vivo
por: Thompson, Karen J., et al.
Publicado: (2018) -
Hypodopaminergic state of the nigrostriatal pathway drives compulsive alcohol use
por: Goutaudier, Raphaël, et al.
Publicado: (2022) -
Off-label Medication Use: A Double-edged Sword
por: Agarwal, Vandana
Publicado: (2021) -
A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome
por: Poulsen, Marianne Ø., et al.
Publicado: (2021)